Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.

Asamer, E, Szkandera, J, Gibiser, P, Lembeck, AL, Stojakovic, T, Kornprat, P, Lackner, C, Winder, T, Schlick, K, Stoger, H, Gerger, A, Pichler, M, Stotz, M. WIEN KLIN WOCHENSCHR. 2018, 130(19-20): 569-574.

Endolysosomal protease susceptibility of Amb a 1 as a determinant of allergenicity.

Wolf, M, Aglas, L, Twaroch, TE, Steiner, M, Huber, S, Hauser, M, Parigiani, MA, Hofer, H, Ebner, C, Bohle, B, Briza, P, Neubauer, A, Stolz, F, Wallner, M, Ferreira, F. J Allergy Clin Immunol. 2018, 141(4):1488-1491.e5.

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.

Westphal, T, Rinnerthaler, G, Gampenrieder, SP, Niebauer, J, Thaler, J, Pfob, M, Fuchs, D, Riedmann, M, Mayr, B, Reich, B, Melchardt, T, Mlineritsch, B, Pleyer, L, Greil, R. Cancer Med. 2018.

Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT.

Huber, S, Lang, R, Steiner, M, Aglas, L, Ferreira, F, Wallner, M, Hawranek, T, Gadermaier, G. Clin Transl Allergy. 2018, 8: 39.

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.

Schlick, K, Magnes, T, Ratzinger, L, Jaud, B, Weiss, L, Melchardt, T, Greil, R, Egle, A. PLoS One. 2018, 13(11): e0206688.

ASCO 2018 highlights: metastatic breast cancer.

Rinnerthaler, G, Gampenrieder, SP, Greil, R. MEMO-MAG EUR MED ONC. 2018, 11(4): 276-279.

T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Catakovic, K, Klieser, E, Neureiter, D, Geisberger, R. Cell Commun Signal. 2017, 15(1):.

Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Aberger, F, Hutterer, E, Sternberg, C, Del Burgo, PJ, Hartmann, TN. Cell Commun Signal. 2017, 15(1): 8.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter, B, Willenbacher, E, Willenbacher, W, Egle, A, Neumeister, P, Voskova, D, Mayerhoefer, ME, Simonitsch-Klupp, I, Melchardt, T, Greil, R, Raderer, M. Blood. 2017, 129(3):383-385.

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.

Wolff, F, Leisch, M, Greil, R, Risch, A, Pleyer, L. Cell Commun Signal. 2017, 15(1):13.